Tamsulosin Hydrochloride Capsule
Product Images NDC 50090-6699

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tamsulosin Hydrochloride (NDC 50090-6699). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500906699)

Label for Tamsulosin Hydrochloride 0.4 mg capsules by A-S Medication Solutions. It includes storage instructions to keep between 68 to 77 degrees Fahrenheit and avoid excessive moisture. Package contains 30 capsules and displays the NDC number 50090-6699-0, with directions to see the package insert for dosage information.*

FDA Label Image

Figure (Tamsulosin Fig1)

A line graph showing mean plasma concentrations of Tamsulosin Hydrochloride over 36 hours after a single 0.4 mg oral dose, comparing fasted versus fed conditions in eight subjects. The y-axis represents plasma concentration (ng/mL), and the x-axis represents time (hours). Two lines indicate higher peak plasma levels in the fasted state compared to the fed state.*

FDA Label Image

Figure (Tamsulosin Fig2)

Figure 2A is a line graph showing the mean change from baseline in total AUA symptom score (0 to 35) over the duration of treatment in weeks. The graph compares three treatment groups labeled as 0.8 mg, 0.4 mg, and placebo. The y-axis represents mean change, and the x-axis represents weeks of treatment, listing sample sizes for each time point. The graph tracks symptom score changes up to 13 weeks and the last observation carried forward (LOCF) time point.*

FDA Label Image

Figure (Tamsulosin Fig3)

A line graph titled "Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 2" showing mean change over treatment duration in weeks (0 to 13). The graph compares three treatments: 0.8 mg, 0.4 mg, and placebo, with data points for each treatment group and sample sizes indicated below each week point.*

FDA Label Image

Figure (Tamsulosin Fig4)

A line chart titled 'Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 1' showing mean changes over a treatment duration of up to 13 weeks. The chart compares three groups: 0.8 mg dosage, 0.4 mg dosage, and placebo, illustrating trends in peak urine flow rate improvements across these treatments.*

FDA Label Image

Figure (Tamsulosin Fig5)

A line graph titled 'Figure 3B Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 2' showing the mean change in urine flow rate over a 13-week treatment period. It compares three lines representing 0.8 mg, 0.4 mg doses, and placebo, with the y-axis from 0.0 to 3.0 mL/sec and the x-axis labeled by weeks of treatment and sample size at each point.*

FDA Label Image

Chemical Structure (Tamsulosin Str)

Chemical structure diagram of tamsulosin hydrochloride showing its molecular components and bonds, including aromatic rings, functional groups, and the hydrochloride ion.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.